
    
      BLU-5937 is a selective P2X3 receptor antagonist being developed for the treatment of chronic
      cough. This Phase 1 study will investigate the safety, tolerability and pharmacokinetics of
      ascending single and multiple doses of BLU-5937 administered orally to healthy volunteers.
    
  